Applied DNA Sciences, Inc.: Applied DNA and Evvivax Initiate Phase I of Clinical Trial to Evaluate LinearDNA COVID-19 Vaccine Candidate for Feline Veterinary Market
(2) - Vaccine Candidate Previously Demonstrated Antibodies and T-cell Response in Mouse Models - Clinical Trial to Serve as Initial Validation of LinearDNA Platform in Large Mammals with Potential Advantages in Manufacturing, Storage, and Distribution over Other Vaccines Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. ("Evvivax"), today announced the initiat...
United States Joseph Impellizeri Jamesa Hayward Luigi Aurisicchio Us Department Of Agriculture Sciences Inc
Source: finanznachrichten.de